Skip to content
Pharma Observatory a Scientist.com platform

Organization (Industry)

Allergan (India)

ClinicalTrials.gov lists Allergan (India) as lead sponsor of 505 trials. It has 7 active development programs and 119 approved assets.

IN Industry Manufacturer
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

69 0 1995 2026

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.4 trial starts a year over the five years to September, under the 5 a year the method needs.

Logo Allergan, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.

This page covers Allergan (India): 505 lead-sponsored trials and 13 legal-entity registrations.

Get the Allergan (India) report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (190)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Glaucoma 98
Dry Eye Syndromes 64
Glaucoma, Open-Angle 56
Macular Degeneration 50
Macular Edema 35

Trials by start year as sponsor or collaborator (26)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2023 1
2022 5
2021 19
2020 23
2019 28
2018 44
2017 26
2016 35
2015 34
2014 69

Recruitment duration, a model prediction: none of the 505 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (7)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Atogepant Migraine Disorders Phase 3 4
REFRESH TEARS Dry Eye Syndromes Phase 3 3
011516X (New Artificial Tear Formulation) Dry Eye Syndromes Phase 3 1
Pilocarpine Presbyopia Phase 3 1
Systane Ultra Multidose Dry Eye Syndromes Phase 3 1

Approved assets (119)

Shown in this order: max phase first.

Approved assets
Drug Trials
BOTULINUM TOXIN TYPE-A 88
Ranibizumab 11
Dexamethasone Intravitreal Implant 10
DEXAMETHASONE 10
Bimatoprost 0.01% 8

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
54% hit target (n=84) 35% on time (n=92)

Journals published in (250)

Shown in this order: most published in first.

Journals published in
Journal Publications
Ophthalmology 33
Archives of ophthalmology (Chicago, Ill. : 1960) 23
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 22
Clinical ophthalmology (Auckland, N.Z.) 19
American journal of ophthalmology 16

US granted patents (1)

Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.

US granted patents
US patents granted Granted in the last 5 years Most recent grant
2,318 43 2025-09-09

FDA import refusals (1)

FDA import refusals
Refused import lines Latest refusal
5 2021-07-21

Organization relationships (46)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
TARIS Biomedical, Inc. Co sponsors trial with 4
Johns Hopkins University Co sponsors trial with 2
University of California System Co sponsors trial with 2
Government of the United States of America Co sponsors trial with 2
Vanderbilt University Co sponsors trial with 2

Latest dated events (3,211)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-08-13 FDA import refusal FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment)
2026-08-13 FDA import refusal FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment)
2026-07-24 FDA import refusal FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment)
2026-07-24 FDA import refusal FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment)
2026-07-11 FDA import refusal FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment)

Biomarker capability evidence (416)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
AATF Trial sponsor Named in trial inclusion criteria
AATF Trial collaborator Named in trial inclusion criteria
ACTG1 Trial collaborator Named in trial inclusion criteria
AGA Trial sponsor Named in trial inclusion criteria
ANGPT2 Trial collaborator Primary endpoint in a Phase 3 trial

On Scientist.com

Allergan (India) is listed as a research supplier in the Scientist.com network.

Service areas

Biology

Allergan is a global, technology-driven multi-specialty health care company pursuing therapeutic advances to help patients live life to their fullest potential. In making this commitment, we work to develop an unparalleled level of insight into patients' wants and needs — and into the priorities and concerns of the medical specialists who treat them. To this end, we employ more than 50 percent of our work force in either research and development (R&D) or sales, ensuring our efforts are focused on innovation and our customers. Allergan's flagship franchises in eye care, neurosciences...

Show the full description

Allergan is a global, technology-driven multi-specialty health care company pursuing therapeutic advances to help patients live life to their fullest potential. In making this commitment, we work to develop an unparalleled level of insight into patients' wants and needs — and into the priorities and concerns of the medical specialists who treat them. To this end, we employ more than 50 percent of our work force in either research and development (R&D) or sales, ensuring our efforts are focused on innovation and our customers.
Allergan's flagship franchises in eye care, neurosciences, medical dermatology and urologics are structured under the company's pharmaceutical business portfolio, Allergan Pharmaceuticals. This portfolio offers specialty physicians and their patients a wide range of treatments to help preserve and protect sight, reduce physical disability and enhance quality of life.
With the acquisition of Inamed Corporation in 2006, Allergan added breast aesthetics and dermal fillers to its business portfolio to create a world-leading medical aesthetics franchise. The acquisition also gained Allergan a leading product portfolio in obesity intervention that offers minimally invasive devices to help patients achieve sustained weight loss and reduce health risks associated with obesity. All of these products are now represented within the Allergan Medical corporate division.
With specialty product lines focused on high-growth markets, Allergan represents a new multi-specialty health care model for the future, where diversification and focus live together to offer physicians and patients best-in-class treatments and a robust pipeline for continuous innovation. Bolstered by an integrated R&D organization and global infrastructure, characteristics of some of the industry's largest pharmaceutical companies, Allergan also maintains a lean and efficient operation with solid growth prospects, like many smaller and more specialized organizations in the health care field. Allergan is large enough to command sufficient resources to address significant patient needs yet small enough for nimble execution. As we look to the future, we will continue to follow our R&D technologies into additional specialty areas and build a leadership presence of relevance to the doctors and patients we serve.

Website
agn.client.shareholder.com/releasedetail.cfm?ReleaseID=592530

Source: Scientist.com supplier network

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.

Work with Allergan on Scientist.com

For prices, more details, or to contact Allergan, visit Scientist.com.

Sign in to Scientist.com to open this supplier in your organization's marketplace.